September 25, 2015
Mitsubishi Tanabe Pharma Corporation (MTPC) has signed an agreement with MedImmune, AstraZeneca’s biologics R&D arm, to collaborate on the development of antibody drug conjugates (ADCs) for cancer therapy, the two companies said. Under the deal, the pair will combine antibodies...read more